FOLH1 and neoplasm: Recently, ligands for prostate-specific membrane antigens have been introduced into positron emission tomography for the diagnosis and management of PCa and have been useful in identifying the location of PCa and assessing tumor volume, which cannot be determined by MRI [28,29].